PMC:7507645 / 4435-4709 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7507645","sourcedb":"PMC","sourceid":"7507645","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7507645","text":"A description of the randomized, double-blind, placebo-controlled, parallel-group phase 3 HALO CM study (NCT02621931), which included a screening visit, 28-day pretreatment period, 12-week treatment period, and final evaluation (week 12), has been published previously [16].","tracks":[{"project":"TEST0","denotations":[{"id":"32958075-237-243-1506671","span":{"begin":270,"end":272},"obj":"[\"29171818\"]"}],"attributes":[{"subj":"32958075-237-243-1506671","pred":"source","obj":"TEST0"}]},{"project":"2_test","denotations":[{"id":"32958075-29171818-60560878","span":{"begin":270,"end":272},"obj":"29171818"}],"attributes":[{"subj":"32958075-29171818-60560878","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"TEST0","color":"#eca493","default":true},{"id":"2_test","color":"#939bec"}]}]}}